Drug Profile

CS 060380

Alternative Names: CS-060380

Latest Information Update: 22 Apr 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Cascade Pharmaceuticals
Class Hepatoprotectants; Obesity therapies; Small molecules
Mechanism of Action Thyroid hormone receptor beta agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase II Non-alcoholic steatohepatitis; Obesity

Most Recent Events

02 Apr 2026 Phase-II clinical trials in Non-alcoholic steatohepatitis (Adjunctive treatment) in China (PO) (NCT07466017)
02 Apr 2026 Phase-II clinical trials in Obesity (Adjunctive treatment) in China (PO) (NCT07466017)
12 Mar 2026 Cascade Pharmaceuticals plans a phase-II trial for Non-alcoholic steatohepatitis and Obesity (Combination therapy, In adults, In the elderly) in China (PO) in April 2026 (NCT07466017)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com